Provectus Pharma (PVCT)

$0.19 0.0008 (0.42%)

14:14 EDT PVCT Stock Quote Delayed 30 Minutes

PVCT Stock Earnings: Provectus Reported Results for Q4 2023

By InvestorPlace Earnings Mar 28, 2024

Provectus just reported results for the fourth quarter of 2023.

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 17,057

Day's Range $0.19 - $0.19

52-Week Range $0.06 - $0.22

Dividend & Yield N/A (N/A)

PVCT Stock Predictions, Articles, and Provectus Pharma News

From the Web

Provectus Biopharmaceuticals Announces Presentation of Full Study Data from Metastatic Neuroendocrine Cancer Phase 1 Trial of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

From BusinessInsider Jun 4, 2021

— Systemic disease control achieved in heavily pre-treated liver cancer patients — 83% DCR; median PFS of 9.2 months; median OS of 22.5 ...

Provectus Biopharmaceuticals Announces Presentation of PV-10® Pancreatic Cancer Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

From BusinessInsider Nov 16, 2020

KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H. Lee Moffitt Cancer Center (Moffitt) presented n...

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Melanoma Abstract for Oral Presentation at Melanoma Bridge 2020

From BusinessInsider Nov 12, 2020

KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing Phase 1b/2 study o...

Provectus concludes patient enrollment in early-stage neuroendocrine tumors study (OTCMKTS:PVCT)

From Seeking Alpha Oct 5, 2020

Provectus (OTC:PVCT -2.9%) has completed enrollment of 12 patients for its Phase 1 of cancer immunotherapy PV-10, an injectable formulation of its proprietary rose bengal disodium, for the treatment of symptomatic neuroendocrine tumors metastatic to the liver, refractory to somatostatin analogs and peptide receptor radionuclide therapy.Recently, the company announced positive preliminary data from its Phase 1b/2 study of PV-10 in combination with Merck's KEYTRUDA for cutaneous melanoma in patients.The company plans to seek end-of-phase meeting with Australia’s Therapeutic Goods administration in Q1 2021.

Provectus' oncolytic immunotherapy shows positive action mid-stage melanoma study (OTCMKTS:PVCT)

From Seeking Alpha Sep 17, 2020

OTC company Provectus (OTC:PVCT +3.0%) has announced preliminary data from its Phase 1b/2 study of PV-10 in combination with Merck's KEYTRUDA for the treatment of advanced cutaneous melanoma in patients who did not respond to single- and dual-agent checkpoint blockade (CB) treatment.

Provectus Biopharma expands RBD research collaboration for cancer treatment (OTCMKTS:PVCT)

From Seeking Alpha Aug 13, 2020

Provectus (OTC:PVCT -1.9%) has expanded its sponsored research collaboration with the University of Calgary, under which the research team will now investigate oral dosing of Provectus's rose bengal disodium (RBD) in in vivo murine models for refractory adult solid tumors that are high-risk phenotypes and have high metastatic potential.Preliminary findings of the research show oral dosing of RBD is effective and well tolerated in an in vivo pediatric leukemia murine model.

ADVERTISEMENT